Noninvasive assessment of characteristics of novel anti-HER2

Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations - eClinicalMedicine

Noninvasive assessment of characteristics of novel anti-HER2 antibodies by molecular imaging in a human gastric cancer xenograft-bearing mouse model

New Approach May Help Predict HER2+ Tumor Response to Treatment – Consult QD

Frontiers Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis

Subtyping of metastatic breast cancer based on plasma circulating tumor DNA alterations: An observational, multicentre platform study - eClinicalMedicine

Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with 18F-FDG and 89Zr-Trastuzumab PET

Expression of anti-HER2 scFv by SHuffle® strains containing pET-22

Frontiers Pre-Clinical Study of the [18F]AlF-Labeled HER2 Affibody for Non-Invasive HER2 Detection in Gastric Cancer

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

Development of a Novel HER2-Targeted Peptide Probe for Dual-Modal Imaging of Tumors

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer - eBioMedicine

Molecules, Free Full-Text

Competitive binding assay of Trastuzumab and anti-HER2 scFv to HER2.

Evaluation of 89Zr-pertuzumab in Breast Cancer Xenografts

Summary of bioinformatics analysis that were used for HER2 peptide